A Phase 2 interventional study of Lu-PSMA-617 in Liver Cancer, Hepatocellular Carcinoma and Metastatic Liver Cancer, sponsored by Melissa Lumish. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Melissa Lumish · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 630th largest by planned enrollment of the 775 interventional ones that give a count, is one of 36 that started in 2026, is one of 259 in phase 2, reaches primary completion later than 63 of the 244 other live ones, and was the 865th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
926 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 336 · Phase 2 376 · Phase 3 66 · Phase 4 14
First in 1977; this study’s year is marked. 36 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 775 interventional studies, 132 across the 121 observational. Of the 602 that completed or were terminated, 262 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
318 of 926 have an industry lead sponsor. The 10 most frequent:
Melissa Lumish is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Melissa Lumish has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Hepatocellular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT01918683Abramson Cancer Center at Penn MedicineTACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | 2026-12 |
| NCT04410302University of California, DavisPatient-Derived Xenografts to Reduce Cancer Health Disparities | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, with more than 900,000 newly diagnosed cases and approximately 830,000 deaths in 2020. Surgical resection and liver transplantation are potential curative options for patients with early-stage HCC. However, most patients present with metastatic and/or unresectable disease and systemic treatment is the only therapeutic option for these patients.
Although several ICI-based combination therapies have recently extended survival for many patients with HCC, biomarker-directed strategies are limited for this disease. Prostate Specific Membrane Antigen (PSMA) is a protein that is expressed in prostate cells and overexpressed in prostate cancer and is accepted as a valuable theragnostic (combined diagnostic and therapeutic) target in metastatic castration-resistant prostate cancer. 68Ga-PSMA-11 PET (PSMA PET) is now utilized to select patients with metastatic prostate cancer for PSMA-directed therapy with 177Lu-PSMA-617. PSMA is now known to be expressed in a variety of solid tumors, including HCC, specifically in the neovasculature associated with solid tumors. However, there is a lack of data exploring whether there is a role for PSMA-directed therapy in non-prostate solid tumors.
Investigator performed PSMA IHC on 148 HCCs from surgical resection or liver explant specimens from patients at the Mayo Clinic, and 90% of HCCs showed PSMA immunostaining localized to the tumor endothelium. More than 50% of HCCs showed 31-100% PSMA immunostaining by area. In several cases, the normal liver background did show faint canalicular staining, highlighting the need to distinguish between normal tissue and tumor-associated expression.
In a similar study using immunohistochemistry (IHC) to evaluate PSMA expression in HCC, 79.2% of tumors showed high levels of PSMA expression at any location, with the majority of this expression occurring in a neovascular staining pattern (89.9%). One patient underwent imaging with PSMA PET which demonstrated intense and heterogeneous PSMA uptake in the HCC tumor.
Several additional reports have demonstrated that PSMA expression in HCC can be detected noninvasively by PSMA PET.20,21 Our group at Mayo Clinic prospectively evaluated PSMA uptake using Ga-PSMA PET in patients with treatment-naïve HCC. In 31 patients, 39 lesions were identified. In this study, 64% had high PSMA uptake (grade 3 or 4) and 36% had low PSMA uptake (grade 1 or 2). It is expected that PSMA uptake will be much higher in patients with advanced HCC. PSMA PET has been compared with MRI for detection of HCC and had similar efficacy to MRI in a cohort of 19 patients. Similarly, a meta-analysis of 6 studies including 126 patients imaged with PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in patients with newly diagnosed or recurrent HCC showed a detection rate of greater than 85%.These studies clearly suggest that targeting PSMA could be an attractive target in patients with advanced HCC.
The VISION study was a phase 3 trial investigating the efficacy and safety of 177Lu-PSMA-617 (Lu-177 vipivotide tetraxetan) with standard of care in patients with previously treated metastatic castration-resistant prostate cancer who were identified as PSMA PET-positive. Similarly, the phase III PSMAfore study of Lu-177 vipivotide tetraxetan demonstrated improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer after prior treatment.
In HCC, a recent preclinical study demonstrated that radioligand therapy using [177Lu]Lu-PSMA-617 and [177Lu]Lu-EB-PSMA-617 effectively suppressed tumor growth and prolonged survival time in PSMA-positive HCC xenograft mice. However, this strategy has not been prospectively utilized in patients with HCC after first-line therapy. There is limited clinical data examining the role of PSMA radioligand therapy in HCC. One study included 2 patients with no other systemic therapy options available and demonstrated insufficient tumor radiation dosing by intratherapeutic SPECT/CT-based dosimetry after only a single cycle of therapy. This data is limited by the short treatment course of only 1 cycle, which was inadequate to induce a response, small sample size, and heavy pre-treatment.
Although the pattern of PSMA expression in HCC is distinct from that in prostate cancer, there is evidence from tyrosine kinase inhibitor (TKI) efficacy that targeting the neovasculature via inhibition of angiogenesis in the local tumor environment can limit tumor growth and improve survival.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
This study's planned enrollment of 10 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Melissa Lumish is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥ 1,500/mcL. > 9 g/dL. count ≥ 75,000/mcL. Serum creatinine ≤ 1.5 x institutional or ≥60 mL/min using the Cockroft-Gault formula for participants with creatinine levels >1.5 ULN.
class A or B7.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 177Lu-PSMA-617 7.4 GBq (200 mCi) once every 6 weeks. 177Lu-PSMA-617 is a radiopharmaceutical which will be administered intravenously (IV).
Drug: Lu-PSMA-617
Given IV
Percentage of Participants with PSMA-Avid Lesions on PET Imaging (≥50%)
Study is feasible if at least 1 PSMA-PET positive lesion is identified in at least 50% of the participants in this cohort
Time frame: 12 weeks post intervention
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: 240 days post treatment
Progression free survival (PFS)
PFS will be estimated using Kaplan-Meier method
Time frame: 24 weeks post intervention
Median overall survival(OS)
OS will be estimated using Kaplan-Meier method
Time frame: 52 weeks post intervention
Objective response rate(ORR)
The ORR will be estimated based on the number of participants with clinical response using a binomial distribution and its confidence interval will be estimated using Wilson's method
Time frame: 12 weeks post intervention
Clinical benefit rate
Clinical benefit rate as defined as proportion of participants with objective responses or stable disease at 12 weeks
Time frame: 12 weeks post intervention
Plan to share: No — This is an investigator initiated trial and University hospital will have the access to individual level data
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.
Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 6 months is below that.
Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Melissa Lumish